Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. announced that its subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd., has successfully completed a key clinical trial for HB0017 injection, aimed at treating moderate to severe plaque psoriasis, achieving all primary and key secondary efficacy endpoints [1][2]. Drug Information - Drug Name: HB0017 Injection - Formulation: Injection - Indication: Psoriasis - Registration Category: Class 1 therapeutic biological product [1]. Clinical Trial Details - The Phase III clinical trial included 408 patients with moderate to severe plaque psoriasis in China, demonstrating significant efficacy with a PASI 75 response rate and sPGA 0/1 response rate at week 12 [1]. - The treatment regimen is expected to offer the longest dosing interval among similar products, with efficacy indicators continuing to improve and stabilize during the maintenance phase [1]. - HB0017 shows strong competitive advantages over existing products targeting the same pathway, both in the core treatment phase (first 12 weeks) and the maintenance phase (12-52 weeks) [1]. - Safety profile of HB0017 is favorable, with no new safety signals identified compared to previous studies and similar drugs [1]. Investment and Development Costs - The company has invested approximately RMB 37.205 million in the development of the HB0017 injection project to date [3]. Future Development - In addition to the completed Phase III trial for plaque psoriasis, HB0017 is also undergoing a Phase III trial for ankylosing spondylitis, with positive results from previous Phase II trials [2].

Core Points - Huahai Pharmaceutical announced that its subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd., and its wholly-owned subsidiary, Huabo Biopharmaceutical Technology (Shanghai) Co., Ltd., have successfully completed a key clinical trial for HB0017 injection for the treatment of psoriasis, achieving all primary and key secondary efficacy endpoints [2] Group 1 - The clinical trial was a multicenter, double-blind, randomized, placebo-controlled study [2] - The trial results indicate significant efficacy of HB0017 in treating psoriasis [2] - This development may enhance Huahai Pharmaceutical's position in the biopharmaceutical market [2]

关于子公司药物临床试验进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 2025-119 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 浙江华海药业股份有限公司 银屑病是一种慢性、复发性、免疫介导的炎症性皮肤病，累及全身皮肤及其他 器官系统。我国银屑病的患病率为 0.5%左右，可发生于各年龄段，大约 80%至 90%的银屑病病例为斑块状银屑病。银屑病患者不但患上多种并发症的几率增高， 常合并其他系统性疾病，如心血管疾病、代谢性疾病、肝肾疾病、自身免疫性疾病 等，比如银屑病关节炎、心力衰竭、肥胖症、高血压、糖尿病和代谢综合征等；同 时患者也承受着巨大的精神痛苦，抑郁、焦虑以及身体和精神痛苦双重压力导致的 自杀倾向等精神疾病在银屑病患者中较为常见。因此银屑病是一种严重影响患者身 心健康的疾病，是一个世界性急需解决的疾患。 HB0017 注射液是华奥泰自主研发的以白介 ...

Core Viewpoint - Huahai Pharmaceutical's HB0017 injection has successfully met primary and key secondary efficacy endpoints in a pivotal clinical trial for the treatment of psoriasis [1][2] Group 1: Clinical Trial Results - The Phase III clinical study for HB0017 injection included 408 patients with moderate to severe plaque psoriasis and achieved all predefined primary efficacy endpoints, including PASI75 and sPGA0/1 at week 12 [2] - The treatment regimen during the maintenance phase is expected to offer the longest dosing interval among similar products, with efficacy indicators continuing to rise and remain stable during this period [2] - HB0017 demonstrated strong competitive advantages in both the core treatment phase (first 12 weeks) and the maintenance phase (weeks 12-52) compared to already marketed products targeting the same pathway [2] Group 2: Safety and Tolerability - HB0017 exhibited good overall safety and tolerability, with adverse event types and severity aligning with expectations based on prior clinical studies and similar drugs, with no new safety risk signals identified [2] Group 3: Product Development and Future Prospects - HB0017 is a monoclonal antibody targeting interleukin-17A (IL-17A) and is intended for treating moderate to severe plaque psoriasis, ankylosing spondylitis, and other autoimmune diseases [3] - In addition to the completed Phase III trial for plaque psoriasis, the company is concurrently conducting a Phase III trial for ankylosing spondylitis, with promising efficacy and safety results from previous Phase II studies [3] - The company has invested approximately RMB 372 million in the development of the HB0017 injection project to date [3]

Core Viewpoint - Huahai Pharmaceutical's HB0017 injection has successfully met primary and key secondary efficacy endpoints in a pivotal clinical trial for the treatment of psoriasis [1][2] Group 1: Clinical Trial Results - The Phase III clinical study for HB0017 injection included 408 patients with moderate to severe plaque psoriasis and achieved all predefined primary efficacy endpoints, including PASI75 and sPGA0/1 at week 12 [2] - The treatment regimen during the maintenance phase is expected to offer the longest dosing interval among similar products, with efficacy indicators continuing to rise and remain stable during this period [2] - HB0017 demonstrated strong competitive advantages in both the core treatment phase (first 12 weeks) and the maintenance phase (weeks 12-52) compared to already marketed products targeting the same pathway [2] Group 2: Safety and Tolerability - The overall safety and tolerability of HB0017 are good, with adverse event types and severity aligning with expectations based on previous clinical studies and similar drugs, with no new safety risk signals identified [2] Group 3: Product Development and Future Plans - HB0017 is a monoclonal antibody targeting interleukin-17A (IL-17A) and is intended for treating moderate to severe plaque psoriasis, ankylosing spondylitis, and other autoimmune diseases [3] - In addition to the completed Phase III trial for plaque psoriasis, the company is concurrently conducting a Phase III trial for ankylosing spondylitis, with promising efficacy and safety data from a Phase II trial [3] - The company has invested approximately RMB 372 million in the development of the HB0017 injection project to date [3]

Group 1: Financing and Investment Plans - Shengyi Electronics plans to raise no more than 2.6 billion yuan through a private placement to invest in AI computing HDI production base, smart manufacturing high-layer circuit board projects, and to supplement working capital and repay bank loans [2] - Lianmicro intends to invest 2.262 billion yuan to construct a project with an annual production capacity of 1.8 million pieces of 12-inch heavily doped substrate wafers [3] - Daimei Co. plans to invest 100 million yuan to establish a wholly-owned subsidiary focused on robotics technology [5] Group 2: Stock Performance and Trading - Furi Shares experienced a significant stock price fluctuation, with an 8-day cumulative deviation of 113.94%, indicating potential irrational speculation [2] - Tianfu Communication has set the initial inquiry transfer price at 140 yuan per share, reflecting a 7.2% discount from the closing price [7] - Ningde Times' third-largest shareholder is transferring shares at a price of 376.12 yuan per share, with full subscription from 16 institutional investors [6] Group 3: Operational Updates - Yongtai Technology's wholly-owned subsidiary is set to begin trial production of a lithium battery additive project with an annual capacity of 5,000 tons, increasing the total capacity to 10,000 tons per year [3] - Trina Solar's subsidiary signed contracts for the sale of 2.66 GWh of energy storage products, which is expected to positively impact future operating performance [5] - Yinglian Co. signed a strategic procurement contract for over 50 million square meters of composite aluminum foil materials for quasi-solid-state batteries, which will enhance its operational development in 2026-2027 [5] Group 4: Corporate Restructuring and Management - Huaxia Happiness has been designated a temporary manager for pre-restructuring by the court, pending a decision on its restructuring application [8] - The National Integrated Circuit Fund has reduced its stake in Shengke Communication by 2.49%, completing its planned share reduction [4]

Core Viewpoint - Huahai Pharmaceutical has received the drug registration certificate for injectable Nicorandil from the National Medical Products Administration, which enhances its product line and market competitiveness [1] Group 1 - Huahai Pharmaceutical announced the approval of injectable Nicorandil on November 17 [1] - The approval allows the product to be considered as having passed the consistency evaluation under the relevant national policies [1] - This new product approval is expected to enrich the company's product offerings [1]

Group 1 - The core point of the article is that Huahai Pharmaceutical has received approval from the National Medical Products Administration for the injection of Nicorandil, which is a significant development for the company [1] - Huahai Pharmaceutical's revenue composition for the year 2024 is as follows: finished drug sales account for 60.32%, raw materials and intermediates sales account for 38.19%, technical services account for 0.66%, other businesses account for 0.55%, and other industries account for 0.28% [1] - As of the report, Huahai Pharmaceutical has a market capitalization of 27.8 billion yuan [1]

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received the drug registration certificate for injectable Nicorandil from the National Medical Products Administration, marking a significant milestone for the company in the cardiovascular drug market [1] Company Summary - The injectable Nicorandil is indicated for unstable angina and was originally developed by Chugai Pharmaceutical Co., Ltd., being launched in Japan in September 1993 [1] - Currently, the domestic market has several manufacturers with the drug registration certificate, including Beijing Four Rings Kebo Pharmaceutical Co., Ltd., Yangtze River Pharmaceutical Group Co., Ltd., and Tianjin Tianshili Zhiqiao Pharmaceutical Co., Ltd. [1] Industry Summary - According to data from Minai Network, the projected domestic market sales for injectable Nicorandil in 2024 are approximately RMB 620 million [1]

申请事项：药品注册（境内生产） | 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 2025-118 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 浙江华海药业股份有限公司 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管 理局（以下简称"国家药监局"）核准签发的注射用尼可地尔的《药品注册证书》， 现将相关情况公告如下： 一、药品的基本情况 药品名称：注射用尼可地尔 剂型：注射剂 规格：12mg 1 根据国家相关政策，公司注射用尼可地尔按化学药品 3 类批准生产可视同通过 一致性评价。该产品的获批进一步丰富了公司的产品线，有助于提升公司产品的市 场竞争力。 四、风险提示 注册分类：化学药品 3 类 申请人：浙江华海药业股份有限公司 药品批准文号：国药准字 H20255924 审批结论：根据《中华人民共和国药品管理法》及有关规定， ...